Quanterix Corporation announced the launch of LucentAD, a test to assist in the evaluation of patients experiencing cognitive symptoms consistent with signs of early Alzheimer’s disease.
According to a release from Quanterix, the LucentAD test — which is expected to become available to health care providers for use in conjunction with other diagnostic tools — will provide clinicians with a simplified assessment process to determine whether a patient presents with amyloid pathology consistent with AD.
The LucentAD test measures the protein p-Tau 18 and its concentration in both plasma and cerebrospinal fluid, whose presence correlates to amyloid pathology in the brain. LucentAD uses the Simoa p-Tau 181 assay, whose high analytical sensitivity allows for detection of p-Tau 181, which is a low-abundance protein in blood. …